Acrivon Therapeutics Inc (ACRV)

12:30 PM

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

12:30 PM

02:04 AM

Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

02:04 AM

May 16, 2025

Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus

May 16, 2025

May 16, 2025

JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus

May 16, 2025

May 15, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com Nigeria

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus

May 15, 2025

May 15, 2025

Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus

May 15, 2025

May 15, 2025

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com

May 15, 2025

May 15, 2025

Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks

May 15, 2025

May 15, 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus

May 15, 2025

May 15, 2025

Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks

May 15, 2025

May 15, 2025

Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025

May 14, 2025

Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 14, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan

May 14, 2025

May 11, 2025

Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World

May 11, 2025

May 08, 2025

(ACRV) Investment Analysis - news.stocktradersdaily.com

May 08, 2025

May 06, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World

May 06, 2025

May 05, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

May 05, 2025

May 05, 2025

Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus

May 05, 2025

May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria

May 05, 2025

May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa

May 05, 2025

May 05, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World

May 05, 2025

May 04, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World

May 04, 2025

May 03, 2025

Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World

May 03, 2025

May 02, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World

May 02, 2025

May 02, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada

May 02, 2025

May 01, 2025

Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks

May 01, 2025

May 01, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com

May 01, 2025

May 01, 2025

You might want to take a look at Acrivon Therapeutics Inc (ACRV) now - Sete News

May 01, 2025

Apr 30, 2025

Acrivon Therapeutics Inc (ACRV)’s stock decline to 1.44 per share - uspostnews.com

Apr 30, 2025

Apr 29, 2025

Major Shareholder Sells Millions in Acrivon Therapeutics Stock! - TipRanks

Apr 29, 2025

Apr 29, 2025

ACRV’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 29, 2025

Apr 28, 2025

Acrivon Therapeutics (ACRV) Sees Surge in Interest Amid Key Deve - GuruFocus

Apr 28, 2025

Apr 28, 2025

KeyBanc Capital Markets initates Acrivon Therapeutics Inc (ACRV) rating to an Overweight - knoxdaily.com

Apr 28, 2025

Apr 25, 2025

Understanding ACRV stock ratios for better investment decisions - uspostnews.com

Apr 25, 2025

Apr 25, 2025

Acrivon Therapeutics Presents Findings on ACR-2316's Mechanisms of Tumor Cell Death at AACR Annual Meeting - Nasdaq

Apr 25, 2025

Apr 25, 2025

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - GlobeNewswire

Apr 25, 2025

Apr 25, 2025

Breakthrough Cancer Drug ACR-2316 Achieves 25% Tumor Reduction with Zero Safety Issues in Phase 1 Trial - Stock Titan

Apr 25, 2025

Apr 24, 2025

Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? - TradingView

Apr 24, 2025

Apr 23, 2025

(ACRV) On The My Stocks Page - news.stocktradersdaily.com

Apr 23, 2025

Apr 22, 2025

April 2025's Standout Penny Stocks - simplywall.st

Apr 22, 2025

Apr 20, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World

Apr 20, 2025

Apr 16, 2025

Acrivon Therapeutics Inc’s Banking’s 100-Day Moving Average at 5.3600: Will the Stock Break Through? - investchronicle.com

Apr 16, 2025

Apr 15, 2025

ACRV’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com

Apr 15, 2025

Apr 14, 2025

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts

Apr 14, 2025